Gateway Wealth Partners LLC Takes Position in Bristol Myers Squibb Company $BMY

Gateway Wealth Partners LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 1st quarter, according to its most recent filing with the SEC. The firm bought 8,986 shares of the biopharmaceutical company’s stock, valued at approximately $545,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC boosted its position in Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares during the last quarter. United Bank grew its stake in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $405,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 3.0%

NYSE:BMY opened at $64.98 on Friday. The company has a market capitalization of $132.70 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $65.56. The stock has a 50-day simple moving average of $57.90 and a 200 day simple moving average of $58.29. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the prior year, the firm posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported second-quarter adjusted EPS of $2.04, well above the $1.60 analyst consensus and up from $1.46 a year earlier. Revenue increased 5.7% year over year to $12.97 billion, exceeding estimates of approximately $11.74 billion. Bristol Myers raises 2026 forecast as Eliquis and newer medicines power results
• Positive Sentiment: The company raised its full-year 2026 outlook to EPS of $6.75-$7.00 and revenue of $49 billion-$50 billion, above consensus forecasts. Management cited strong performance from blood thinner Eliquis and newer products including Camzyos and Reblozyl. Bristol Myers Squibb raises 2026 revenue outlook
• Positive Sentiment: The growth portfolio reportedly expanded 14%, with continued momentum from Opdivo Qvantig, Breyanzi and Iza-bren. Strong cash flow and a valuation viewed as inexpensive relative to large pharmaceutical peers, along with a dividend yield near 4%, supported bullish analyst commentary. Bristol Myers Squibb upgraded to Buy on positive earnings and outlook
• Neutral Sentiment: Analysts noted that the transition away from older products remains incomplete. Opdivo sales declined, while patent expirations and legacy portfolio weakness continue to pressure revenue.
• Negative Sentiment: Delayed clinical readouts for Milvexian and Cobenfy, as well as mixed performance from certain pipeline assets, may limit near-term catalysts. Unusually heavy put-option activity also signals that some traders remain cautious about downside risks. Bristol Myers Squibb second-quarter earnings call highlights

Analyst Ratings Changes

A number of brokerages recently commented on BMY. Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Raymond James Financial restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Bank of America decreased their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.